326 related articles for article (PubMed ID: 31697809)
21. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
Özdemir S; Ton Ö; Kabukcuoğlu F
Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
25. A novel scoring system for TIGIT expression in classic Hodgkin lymphoma.
Annibali O; Bianchi A; Grifoni A; Tomarchio V; Tafuri M; Verri M; Avvisati G; Crescenzi A
Sci Rep; 2021 Mar; 11(1):7059. PubMed ID: 33782477
[TBL] [Abstract][Full Text] [Related]
26. Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.
Samiei A; Gjertson DW; Memarzadeh S; Konecny GE; Moatamed NA
Diagn Pathol; 2022 Sep; 17(1):70. PubMed ID: 36104728
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
[TBL] [Abstract][Full Text] [Related]
30. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironment and RIG-I signaling molecules in Epstein Barr virus-positive and -negative classical Hodgkin lymphoma of the elderly.
Satoh T; Wada R; Yajima N; Imaizumi T; Yagihashi S
J Clin Exp Hematop; 2014; 54(1):75-84. PubMed ID: 24942949
[TBL] [Abstract][Full Text] [Related]
32. Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.
Buettner M; Greiner A; Avramidou A; Jäck HM; Niedobitek G
Hematol Oncol; 2005; 23(3-4):127-32. PubMed ID: 16342298
[TBL] [Abstract][Full Text] [Related]
33. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
34. Assessment of tumor microenvironment expression and clinical significance of immune inhibitory molecule CTLA-4, ligand B7-1, and tumor-infiltrating regulatory cells in Hodgkin lymphoma.
Verma RS; Singh G; Singh A; Singh P
J Med Life; 2023 Apr; 16(4):599-609. PubMed ID: 37305822
[TBL] [Abstract][Full Text] [Related]
35. Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment.
Masel R; Roche ME; Martinez-Outschoorn U
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101514. PubMed ID: 38092473
[TBL] [Abstract][Full Text] [Related]
36. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
37. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.
Tiacci E; Döring C; Brune V; van Noesel CJ; Klapper W; Mechtersheimer G; Falini B; Küppers R; Hansmann ML
Blood; 2012 Nov; 120(23):4609-20. PubMed ID: 22955914
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus.
Zameer MA; Premalata CS; Arunakumari B; Appaji L; Rao CR
Pediatr Hematol Oncol; 2015 May; 32(4):229-38. PubMed ID: 25252151
[TBL] [Abstract][Full Text] [Related]
39. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
40. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
